Takeda Pharmaceutical  Limited logo

Takeda Pharmaceutical Limited

TAK | NYSE
Chart Builder DCF Calculator
$19
+$0.11 (+0.58%)
Sep 22, 2026, 12:15 PM ET · Market open
Fiscal Year
Period Ending
FY 2025
Mar 30, 2026
FY 2024
Mar 30, 2025
FY 2023
Mar 30, 2024
FY 2022
Mar 30, 2023
FY 2021
Mar 30, 2022
FY 2020
Mar 30, 2021
Net Income
-152.13B 108.14B 144.2B 317.04B 230.17B 376.17B
Depreciation & Amortization
721.13B 761.4B 728B 664.4B 583.15B 559.67B
Stock-Based Compensation
72.78B 72.87B 70.87B 60.67B 43.37B 37.66B
Other Working Capital
331.36B 34.56B -155.36B -21.24B 17.46B 259.12B
Other Non-Cash Items
189.98B 107.21B 120.68B -97.74B 95.4B -228.42B
Deferred Income Tax
9.77B 66.94B -91.41B 58.05B 72.41B -9.94B
Change in Working Capital
199.91B -59.37B -256B -25.26B 98.61B 275.78B
Operating Cash Flow
1.04T 1.06T 716.34B 977.16B 1.12T 1.01T
Capital Expenditures
-414.66B -379.63B -480.73B -633.69B -186.04B -236.47B
Cash Acquisitions
33.58B 77.24B 19.96B 7.96B -21.48B 530.39B
Purchase of Investments
-17.43B -111.38B -40.07B -10.15B -8.34B -12.6B
Sales Maturities Of Investments
7.03B 29.44B 8.02B 22.25B 16.92B 74.6B
Other Investing Acitivies
-216.32B -161.57B -276.36B -486.51B -61.98B -87.66B
Investing Cash Flow
-369.14B -367.06B -463.86B -607.1B -198.13B 393.53B
Debt Repayment
1.08B -314.31B 1.51B -285.07B -600.48B -660.5B
Common Stock Repurchased
-51.6B -51.86B -2.33B -26.93B -77.53B -2.14B
Dividend Paid
-311.9B -302.5B -287.19B -279.42B -283.67B -283.36B
Other Financial Acitivies
-134.39B -82.75B -66.42B -117.73B -108.59B -142.35B
Financial Cash Flow
-496.82B -751.43B -354.42B -709.15B -1.07T -1.09T
Net Cash Flow
209.94B -72.69B -75.73B -316.17B -116.53B 328.61B
Free Cash Flow
626.77B 677.56B 235.61B 343.47B 937.07B 774.46B
Adj. Free Cash Flow
554B 604.69B 164.74B 282.8B 893.69B 736.8B
Maintenance CapEx
-328.39B -235.02B -374.83B -435.78B -29.65B -236.47B
Growth CapEx
-86.27B -144.61B -105.9B -197.91B -156.39B n/a
Owner Earnings
713.04B 822.16B 341.51B 541.38B 1.09T 774.46B

© 2026 bestshares.com. All rights reserved.